...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort
【24h】

Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort

机译：从Net-PD LS-1队列中预期治疗帕金森病中减肥损失的预测因素

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life. Predictors of weight loss have not been studied in large clinical cohorts. We previously observed an association between change in body mass index and change in Unified Parkinson's Disease Rating Scale (UPDRS) motor and total scores. In this study, we performed a secondary analysis of longitudinal data (1-6 years) from 1619 participants in the NINDS Exploratory Trials in PD Long-term Study-1 (NET-PD LS1) to explore predictors of weight loss in a large prospective clinical trial cohort of early treated Parkinson's disease. The NET-PD LS1 study was a double-blind randomized placebo controlled clinical trial of creatine monohydrate 10 gm/day in early treated PD (within 5 years of diagnosis and within 2 years of starting dopaminergic medications). Linear mixed models were used to estimate the effect of baseline clinical covariates on weight change over time. On average, participants lost only 0.6 kg per year. Higher age, baseline weight, female gender, higher baseline UPDRS scores, greater postural instability, difficulty eating and drinking, lower cognitive scores and baseline levodopa use (compared to dopamine agonists) were all associated with weight loss. Surprisingly baseline difficulty swallowing, dyskinesia, depression, intestinal hypomotility (constipation) and self-reported nausea/vomiting/anorexia were not significantly associated with weight loss in this cohort of early treated Parkinson's disease patients. On average, participants with Parkinson's disease experience little weight loss during the first 1-6 years after starting dopaminergic replacement therapy, however levodopa use and postural instability were both predictors of early weight loss.
机译：减肥是帕金森病的常见症状，与生活质量受损有关。在大型临床队列中尚未研究体重减轻的预测因素。我们之前观察到体重指数变化与统一帕金森病评级规模（UPDRS）电机和总分数之间的关系。在这项研究中，我们在PD长期研究-1（NET-PD LS1）中的NINDS探索性试验中的1619名参与者中对纵向数据（1-6岁）进行了二次分析，以探索大型前瞻性重量损失的预测因素早期治疗帕金森病的临床试验队列。 Net-Pd LS1研究是一种双盲随机安慰剂对受控临床试验的肌酸一水合物10克/天在早期治疗的PD（诊断5年内，在2年内开始多巴胺能药物）。线性混合模型用于估算基线临床协变量随时间随时间的重量变化的影响。平均而言，参与者每年只失去0.6千克。年龄较高，基线重量，女性性别，更高的基线updrs分数，更高的姿势不稳定，难以饮用，较低的认知评分和基线左旋多巴使用（与多巴胺激动剂相比）都与减肥相关。令人惊讶的基线困难吞咽，止吐瘤，抑郁症，肠道空缺症（便秘）和自我报告的恶心/呕吐/厌食并没有显着与这种早期治疗帕金森病患者的减肥无关。平均而言，在开始多巴胺能替代疗法后，帕金森病的参与者在前1 - 6年内遇到少量减肥，但左旋多巴使用和姿势不稳定都是早期减肥的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号